Therapy Areas: Vaccines
10x Genomics Partners with BioLegend and Immudex to Extend Research Applications of Its New Single Cell Feature Barcoding Technology
1 August 2018 - - US-based genomic discovery company 10x Genomics, Inc. said that US-based antibodies and reagents developer BioLegend and Norwegian diagnostics developer Immudex will be the first 10x Compatible Partners providing products for its new single cell Feature Barcoding Technology, which was revealed at the 2018 Advances in Genome Biology and Technology meeting in February this year.

The resulting product innovations, available at the end of 2018, will enable simultaneous gene and protein expression of the same cell as well as cellular characterizations and mapping responses.

The newly developed applications have potential to accelerate disease research and drug discovery in oncology, neurology, infections disease, and immunology in addition to enhancing cell atlas research initiatives.

The co-development partnership with BioLegend will result in the first commercially offered ready to use solution for simultaneous measurement of highly-multiplexed protein and unbiased gene expression from single cells, similar to previously reported academic methods, CITE-seq and REAP-seq.

The new products offered by BioLegend, TotalSeq B and TotalSeq C, will be fully compatible with 10x Genomics' Chromium Single Cell Gene Expression Solution or Single Cell Immune Profiling Solution with Feature Barcoding Technology.

The additional partnership with Immudex leverages its proprietary Dextramer technology to interrogate antigen-binding specificity alongside the transcriptome and repertoire readouts at single cell resolution.

Using the 10x Chromium Single Cell Immune Profiling Solution with new Feature Barcoding Technology and Immudex DNA barcoded MHC-peptide multimers, researchers will be able to link full-length, paired TCR alpha and beta chain sequences and transcriptional profiles to the identity of their target antigens in the same cells with high specificity and sensitivity.

BioLegend develops and manufactures antibodies and reagents. The product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more.

The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a range of custom services, including assay development, sample testing, and conjugation.

BioLegend headquarters in San Diego, California operates under an ISO 13485:2003 certified quality management system.

Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex manufactures MHC Dextramer for the detection of antigen-specific T cells.

Immudex's MHC Dextramer products are utilised for the quantification or sorting of antigen-specific T cells in life science research, in vitro diagnostics, as well as the development of immunotherapeutics and vaccines. The CE and FDA 510(k) cleared Dextramer CMV Kit is approved for in vitro diagnostic use for the quantification of CMV-specific T cells. GMP Grade reagents are available.

dCODETM DNA tagged Dextramer reagents enable massive multiplexing of antigen-specific T cell detection via PCR and next generation sequencing.
Login
Username:

Password: